01.08.2014 Vita 34 AG  DE000A0BL849

DGAP-Adhoc: Vita 34 AG: Management and supervisory board rely on continuity in the corporation


 
Vita 34 AG / Key word(s): Change of Personnel 01.08.2014 18:27 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Vita 34 AG: Management and supervisory board rely on continuity in the corporation - Management contract extended: Dr. André Gerth reappointed as CEO until 2018 - Internal changeover in supervisory board: Dr. Giering takes seat of chairman of supervisory board; previous chairman Dr. Födisch remains member of the board Leipzig, 1 August 2014 -Vita 34 AG (WKN A0BL84), the largest private stem cell bank in the German-speaking countries, provides for continuity in the corporation by reappointing Dr. André Gerth as CEO until 2018 and an internal changeover in the supervisory board. In today's meeting the supervisory board of Vita 34 AG has reappointed Dr. Gerth as the corporation's CEO from 1 August 2014 to 31 December 2018. The supervisory board thus expresses once again its confidence in Dr. Gerth and recognizes his previous performance as CEO of Vita 34 AG. Beyond that, Dr. Gerth emphasizes his commitment to Vita 34 AG by extending the lock-up agreement for his Vita 34 shares by another 18 months. The management board appreciates Dr. Gerth's clear proof of confidence. At the same time, the supervisory board elected Dr. Hans-Georg Giering, so far vice chairman of the supervisory board, the new chairman. He takes over the position from Dr. Holger Födisch with immediate effect. Dr. Giering has approved expertise from acting as the CEO of a quoted, successful company for almost 15 years. He will contribute this experience to his new position as the chairman of the supervisory board at Vita 34 AG. Dr. Födisch will continue to actively support the corporation as vice chairman of the supervisory board in the future. 01.08.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: [email protected] Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 19,19 20,41 19,93 20,07 28,42 68,94 76,80
EBITDA1,2 1,85 4,72 5,43 5,34 0,81 -3,56 4,00
EBITDA-Marge3 9,64 23,13 27,25 26,61 2,85 -5,16
EBIT1,4 0,14 2,63 2,45 2,38 -3,07 -27,28 -4,65
EBIT-Marge5 0,73 12,89 12,29 11,86 -10,80 -39,57 -6,06
Jahresüberschuss1 -0,33 0,83 0,72 1,50 -3,93 -27,38 -5,20
Netto-Marge6 -1,72 4,07 3,61 7,47 -13,83 -39,72 -6,77
Cashflow1,7 1,53 4,60 6,32 3,98 2,73 -4,49 0,00
Ergebnis je Aktie8 -0,09 0,20 0,18 0,37 -0,63 -1,71 -0,29
Dividende8 0,16 0,16 0,00 0,00 0,00 0,00 0,16
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vita 34
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0BL84 4,980 Halten 87,85
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
19,15 25,96 0,70 -71,14
KBV KCV KUV EV/EBITDA
8,07 - 1,14 22,22
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 28.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2024 30.08.2024 22.11.2024 30.04.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,30% 2,15% -4,96% -15,59%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vita 34 AG  ISIN: DE000A0BL849 können Sie bei EQS abrufen


Biotechnologie , A0BL84 , V3V , XETR:V3V